Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | GFER | P55789 | 2/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | STK25 | O00506 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5362896 | 1.00 | LMNA (0.49) | LMNACA1CA2CA9MEN1 | |
| SCHEMBL5374184 | 0.87 | CYP1A2 (0.46) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5365390 | 0.87 | CYP1A2 (0.46) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5365395 | 0.87 | CYP1A2 (0.46) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5356452 | 0.86 | KMT2A (0.60) | LMNAMEN1KMT2AALDH1A1BLM | |
| SCHEMBL5356457 | 0.86 | KMT2A (0.60) | LMNAMEN1KMT2AALDH1A1BLM | |
| SCHEMBL5367570 | 0.84 | KMT2A (0.45) | LMNACA1CA2CA9MEN1 | |
| SCHEMBL5359445 | 0.84 | KMT2A (0.45) | LMNACA1CA2CA9MEN1 | |
| SCHEMBL5359439 | 0.84 | KMT2A (0.45) | LMNACA1CA2CA9MEN1 | |
| SCHEMBL5361131 | 0.83 | KDM4E (0.42) | LMNAMEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030180236-A1 | Resorcinol derivatives | PFIZER PRODUCTS, INC. | 2003-09-25 | — | — | US | claimed |
| US-7282592-B2 | Resorcinol derivatives | WARNER-LAMBERT COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070122367-A1 | RESORCINOL DERIVATIVES | PFIZER INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-6852747-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1317425-B1 | RESORCINOL DERIVATIVES | PFIZER PROD INC (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20030180236-A1 | Resorcinol derivatives | PFIZER PRODUCTS, INC. | 2003-09-25 | — | — | US | disclosed |
| US-6590105-B2 | For skin lightening or depigmentation; works by inhibiting tyrosinase in humans; kits | WARNER-LAMBERT COMPANY | 2003-07-08 | — | — | US | disclosed |
| US-20020114770-A1 | Resorcinol derivatives | PFIZER INC. | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070122367-A1 | RESORCINOL DERIVATIVES | LRAT, NQO1, ALDH1A2 | LMNA 1644/4885CA1 4874/4885CA2 3565/4885 |
| US-20030180236-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | LMNA 1644/4885CA1 4874/4885CA2 3565/4885 |
| US-20020114770-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | LMNA 1644/4885CA1 4874/4885CA2 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.